PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.


Suzanne Lentzsch, MD, PhD - A New Treatment Era for Light Chain Amyloidosis: Interprofessional Lessons From a Center of Excellence

Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discusses a team-based approach to the management of light chain (AL) amyloidosis. Hear from Suzanne Lentzsch, MD, PhD, Mathew S. Maurer, MD, and Margaret Cuomo, MSN, FNP-C, from the Columbia University Medical Center, as they give insights on diagnostic strategies for AL amyloidosis and as they explore treatment guidelines, evidence, and safety concerns of established and novel approaches to managing AL amyloidosis. Upon completion of this accredited CE activity, participants should be better able to: Summarize the distinct clinical features, symptoms, and clinical course of light chain (AL) amyloidosis, Develop team-based diagnostic and assessment strategies that capture relevant symptoms, differentiate AL amyloidosis from other disease subtypes, and characterize disease-related complications in the heart, kidneys, skin, liver, and other organ systems, Discuss current guidelines and evidence supporting established and novel approaches to managing AL amyloidosis and related cardiac or renal dysfunction, Design team-based management plans that safely incorporate novel therapies into the management of patients with AL amyloidosis.


 2021-07-31  57m